Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course

…, GD Sebastiani, A Iuliano, G Emmi, D Cammelli… - Journal of clinical …, 2019 - mdpi.com
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …

Alkaptonuria, ochronosis, and ochronotic arthropathy

…, S Lorenzini, M Giorgi, P Airó, D Cammelli… - Seminars in arthritis and …, 2004 - Elsevier
OBJECTIVES: To describe the clinical presentation and course of a relatively large group of
Italian adult patients screened for mutation of the homogentisate dioxygenase gene causing …

Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: a multicentre retrospective observational study

…, E Baldissera, E Bartoloni, D Cammelli… - Frontiers in …, 2017 - frontiersin.org
Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset Still’s
disease (AOSD). Objectives: To evaluate the efficacy and safety of anakinra (ANA) and …

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center …

…, R Gallizzi, A Soriano, M Alessio, D Cammelli… - Frontiers in …, 2016 - frontiersin.org
Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic
options in a large number of old and new clinical entities characterized by an IL-1 driven …

Bench to bedside review of myositis autoantibodies

…, G Vitiello, A Carraresi, MG Giudizi, D Cammelli… - Clinical and Molecular …, 2018 - Springer
Idiopathic inflammatory myopathies represent a heterogeneous group of autoimmune diseases
with systemic involvement. Even though numerous specific autoantibodies have been …

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

…, R Gallizzi, A Soriano, M Alessio, D Cammelli… - Clinical …, 2018 - Springer
A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The
aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in …

Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis

…, M Benucci, S Maddali-Bongi, D Cammelli… - Digestive and Liver …, 2012 - Elsevier
BACKGROUND: Liver stiffness values were recently proposed to identify patients with
methotrexate-induced liver fibrosis. Aim of this study was to assess the clinical and laboratory …

Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab

…, F Nencini, S Pratesi, G Petroni, D Cammelli… - International archives of …, 2012 - karger.com
Rituximab (RTX) is currently used in the treatment of lymphoproliferative diseases and of
several rheumatologic disorders and is a frequent cause of acute infusion reactions, usually …

Aortic connective tissue in ageing—a biochemical study

L Andreotti, A Bussotti, D Cammelli, F di Giovine… - …, 1985 - journals.sagepub.com
The biochemical analysis of samples of aortic connective tissue was carried out in 22 subjects
from 9 to 84 years old. Aortic samples were taken at necropsy performed after sudden or, …

Long-term retention rate of anakinra in adult onset Still's disease and predictive factors for treatment response

…, E Baldissera, E Bartoloni, D Cammelli… - Frontiers in …, 2019 - frontiersin.org
Background: Anakinra (ANA) is an effective treatment choice in patients with adult onset Still’s
disease (AOSD). Variables affecting treatment survival include loss of efficacy or adverse …